Diabetes | CHOP Research Institute
 

Diabetes

Skeletal Health and Diseases Research Affinity Group

Skeletal Health and Diseases RAG

Promoting and fostering new research ventures and collaborations among our community of basic and translational investigators, clinician-scientists, and clinicians with shared interests in skeletal health and diseases

PETITE-T1D

PETITE-T1D

The purpose of this study is to evaluate the safety and pharmacokinetics (drug levels in the blood) of teplizumab in children less than 8 years old.

Designate - Siplizumab in T1DM

Designate - Siplizumab in T1DM

The goal of this study is to identify a safe dosing regimen for siplizumab in participants with type 1 diabetes.

Reaching New Heights With Crossword Puzzles and Radio-controlled Planes

Published on
Jul 29, 2022
in Cornerstone Blog
Reaching New Heights With Crossword Puzzles, Radio-controlled Planes
Dr. Levine’s great pastimes outside of his endocrinology lab are crossword puzzles and flying radio-controlled airplanes with his grandsons.

Celebrate Diversity Month: Q&A With Featured Research Trainee, Anna Ada Dattoli, PhD

Published on
Apr 28, 2022
in Cornerstone Blog
Celebrate Diversity Month: Q&A With Trainee Anna Ada Dattoli, PhD
Our Featured Trainee for April, Anna Ada Dattoli, PhD, discusses Celebrate Diversity Month and her research on diabetes.
Jacquelyn Anne Hatch-Stein, MD
Jacquelyn Anne Hatch-Stein

Dr. Hatch-Stein's research interests include diabetes, thyroid disorders, and disorders of growth and puberty. Recent clinical research projects include "Bone Health and Cardiovascular Risk in Turner Syndrome" and "Patterns of Height Velocity in Down Syndrome."

E-mail:
hatchsteinj [at] chop.edu

Teplizumab in New-Onset Type 1 Diabetes

Teplizumab in New-Onset Type 1 DiabetesTeplizumab in New-Onset Type 1 Diabetes

This is a study that investigates whether an IV medication (teplizumab) will slow or halt the progression of type 1 diabetes in children and adolescents (ages 8 - 17 years).

The Charisma Study

The Charisma Study

We are currently enrolling adolescents ages 15-21 of South Asian ancestry, African American ancestry, and European American or "White" ancestry.

Ertugliflozin for Children and Adolescents with Type 2 Diabetes

Ertugliflozin for Children and Adolescents with Type 2 Diabetes

You are invited to take part in a voluntary research trial because you have type 2 diabetes and are between the ages of 10 and 17 years.

Shah Laboratory

Shah Lab

The Shah Lab investigates obesity and its related complications. Current work includes clinical and translational studies exploring the pathophysiology and modulation of obesity-related adipose tissue and systemic inflammation using human cell lines and clinical trials.